Market prospects
Global Trend: In 2024, the global intimate care market reached US$15 billion (with a CAGR of 8.5%), and the Chinese market is leading the world in growth rate.
Domestic Outbreak: With a female population exceeding 680 million, the incidence rate of gynecological diseases reaches as high as 87.5%, creating a pharmaceutical market worth hundreds of billions of yuan—and patients demonstrate an extremely strong willingness to repurchase.
Addressing pain points such as recurrent episodes and incomplete care in gynecological nursing, “Zi Mei Shu” exclusively holds a national patent and utilizes silver-ion technology to provide a comprehensive, full-cycle health solution encompassing “prevention, conditioning, and maintenance”—a technological barrier that is extremely difficult to replicate.
Comprehensive franchise support to ensure worry-free profitability.
We’ve recruited 360 city partners for precision investment promotion, jointly deploying over 100,000 key outlets (including pharmacies, hospitals, postpartum care centers, and more).
Five Empowerment Systems
Profit Guarantee: Tiered profit margins with substantial profits from core channels.
Market Protection: A strict regional exclusive agency policy to eliminate internal competition.
Brand Sales Promotion: Empowered by a million-dollar marketing fund from headquarters, we provide standardized traffic-driving solutions for platforms such as Xiaohongshu, Douyin, and Taobao.
Worry-free after-sales service: 24/7 expert customer support with rapid response.
Systematic Training: A comprehensive training program featuring "online theory + offline practical exercises" to help you rapidly expand your market.
Profit Outlook: A clear input-output model that shares the benefits of sustained growth.
Leveraging Wan'an Pharmaceutical’s 32-year brand legacy, we sincerely invite visionary individuals to join hands with us in seizing the first-mover advantage in the women’s health market and jointly building a prosperous future!